What Oramed Pharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 2 | 4 |
| Total trades | 9 | 40 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 1,629,715 | 3,669,471 |
| Disposed | 50,000 | 926,428 |
| Net activity | +1,579,715 | +2,743,043 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Gabay Avraham | Chief Financial Officer | Oct 01 | Disclosed 10b5-1 sale · S | −20,000 | $4.51 | −$90.2K | 861,076 |
| Hexter Joshua | COO & CBO | Oct 01 | Disclosed 10b5-1 sale · S | −30,000 | $4.51 | −$135K | 1,328,130 |
| Kidron Miriam | Chief Scientific Officer | Sep 24 | Grant / award · A | +209,291 | — | — | 1,550,554 |
| Kidron Miriam | Chief Scientific Officer | Sep 24 | Grant / award · A | +208,125 | — | — | 1,341,263 |
| Kidron Nadav | President and CEO | Sep 24 | Grant / award · A | +368,765 | — | — | 4,140,505 |
| Kidron Nadav | President and CEO | Sep 24 | Grant / award · A | +349,497 | — | — | 3,771,740 |
| Gabay Avraham | Chief Financial Officer | Sep 24 | Grant / award · A | +209,291 | — | — | 881,076 |
| Hexter Joshua | COO & CBO | Sep 24 | Grant / award · A | +209,291 | — | — | 1,358,130 |
| Hexter Joshua | COO & CBO | Sep 24 | Grant / award · A | +75,455 | — | — | 1,148,839 |
| Hexter Joshua | COO & CBO | Jul 02 | Exercise / conversion · M | +50,000 | $3.69 | +$185K | 1,073,384 |
| Gabay Avraham | Chief Financial Officer | Jul 01 | Disclosed 10b5-1 sale · S | −73,360 | $4.51 | −$331K | 671,785 |
| Hexter Joshua | COO & CBO | Jul 01 | Disclosed 10b5-1 sale · S | −137,000 | $4.46 | −$611K | 1,023,384 |
| Kidron Nadav | President and CEO | Mar 30 | Withheld — tax / exercise cost · F | −44,818 | $3.31 | −$148K | 3,422,243 |
| Kidron Miriam | Chief Scientific Officer | Mar 30 | Withheld — tax / exercise cost · F | −435,084 | $3.31 | −$1.44M | 1,133,138 |
| Gabay Avraham | Chief Financial Officer | Mar 17 | Grant / award · A | +95,889 | — | — | 745,145 |
| Kidron Nadav | President and CEO | Mar 17 | Grant / award · A | +167,005 | — | — | 3,422,243 |
| Hexter Joshua | COO & CBO | Mar 17 | Grant / award · A | +95,889 | — | — | 1,160,384 |
| Kidron Miriam | Chief Scientific Officer | Mar 17 | Grant / award · A | +119,558 | — | — | 1,568,222 |
| Kidron Nadav | President and CEO | Mar 12 | Gift · G | −100,000 | — | — | 3,255,238 |
| Kidron Nadav | President and CEO | Jan 22 | Exercise / conversion · M | +109,000 | — | — | 3,355,238 |
Loading...
